Short answer: telehealth TRT is legal today under a DEA/HHS temporary flexibility that runs through December 31, 2026 — but that waiver does not replace state licensure or real lab-confirmed diagnosis.
Telehealth TRT is legal right now — but "right now" is doing real work in that sentence. Testosterone is a controlled substance, which puts it under a specific set of federal telemedicine rules that are currently operating on a temporary extension with a real expiration date. Here's what's actually going on.
Why Testosterone Gets Special Treatment
Testosterone is classified as a Schedule III controlled substance under the Controlled Substances Act — the DEA specifically lists it as an anabolic steroid in that schedule.[1] Schedule III means it has an accepted medical use but also a recognized potential for abuse, with moderate-to-low physical dependence risk or higher psychological dependence risk — which is exactly why TRT is regulated as a controlled substance rather than an ordinary prescription medication.[1]Practically, that means a valid prescription from a DEA-registered practitioner is required for any legal use; it can't be purchased over the counter, and dispensing or possessing it without a prescription violates federal law.[1]
The Ryan Haight Act and Why It Matters Here
The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 generally prohibits prescribing a controlled substance over the internet without the prescriber having conducted at least one in-person medical evaluation first, absent a specific statutory exception.[2]An "in-person evaluation" specifically means the patient and practitioner are physically together — a video-only telehealth visit doesn't satisfy this requirement on its own, unless it falls under a recognized telemedicine exception or temporary flexibility.[2]
Why Telehealth TRT Is Currently Legal Anyway
Since 2020, DEA and HHS have repeatedly issued temporary flexibilities allowing DEA-registered practitioners to prescribe Schedule II–V controlled substances via telemedicine without a prior in-person visit, as long as all other regulatory conditions are met.[3]The most recent extension — the "Fourth Temporary Extension of the COVID-19 Telemedicine Flexibilities" — was issued December 30, 2025, and runs through December 31, 2026, covering Schedule III drugs like testosterone.[5] This is codified at 42 CFR § 12.1, which authorizes prescribing controlled substances via telemedicine without an in-person evaluation through that date, provided the prescription serves a legitimate medical purpose, is issued in the usual course of professional practice, uses an approved telecommunications system, and complies with all other DEA and state law.[4]
In practice, that means TRT prescribed by a properly licensed, DEA-registered clinician through an audio-video telehealth visit is legally permissible right now — as long as the prescription meets the "legitimate medical purpose" standard, is backed by real diagnostic evaluation (including lab-confirmed hypogonadism, not just a symptom checklist), and follows applicable state medical practice and telehealth law.[3]
This is temporary, not permanent.The flexibility doesn't repeal the Ryan Haight Act — it waives the in-person requirement through December 31, 2026. Absent a permanent rule change before then, the in-person requirement is set to snap back after that date for new controlled-substance starts, including TRT.[5]A JAMA Health Forum review of the DEA's proposed longer-term "special registration" framework notes the agency is trying to balance diversion concerns against legitimate telemedicine access — but as of the most recent published review, that framework was still in proposed rulemaking, not finalized.[7] Anyone starting telehealth TRT now is operating under a rule with a known expiration date, which is worth understanding rather than assuming the current setup is permanent.
Federal Flexibility Doesn't Replace State Licensure Requirements
Even with the DEA extension in place, standard medical licensure rules still apply on top of it. The physician or nurse practitioner treating you has to be licensed (or specifically authorized) in the state where you're physically located, and has to meet the same standard of care for diagnosing hypogonadism and monitoring therapy that would apply in an in-person practice — appropriate labs and follow-up included.[6]The DEA flexibility addresses the federal controlled-substance piece specifically; it doesn't waive any state-level requirement.
The Bottom Line
Telehealth TRT is legitimate and legal today under the current federal telemedicine flexibility — this isn't a gray-market workaround. But it's operating on a temporary rule with a December 31, 2026 expiration, layered on top of standard state licensure requirements that never went away. A legitimate provider should be conducting real diagnostic evaluation (lab-confirmed hypogonadism, not just a questionnaire), staying licensed in your state, and should be able to speak plainly about how these federal rules apply to your specific treatment.
Check directly with any provider how they're structuring care to stay compliant as this flexibility window approaches its current end date — or compare options on RENVA's Men's Health / TRT hub.
Sources
- Testosterone | C19H28O2 | CID 6013 — PubChem (National Institutes of Health) pubchem.ncbi.nlm.nih.gov
- Online Prescribing of Controlled Substances (Ryan Haight Act overview) — American Psychiatric Association Telepsychiatry Toolkit psychiatry.org
- DEA Extends Telemedicine Flexibilities to Ensure Continued Access to Care — U.S. Drug Enforcement Administration dea.gov
- 42 CFR § 12.1 — Temporary extension of certain COVID-19 telemedicine flexibilities for prescription of controlled medications — Legal Information Institute, Cornell Law School law.cornell.edu
- DEA, HHS extend telemedicine waivers through 2026 — American Hospital Association News aha.org
- Licensure & Telehealth — American Medical Association ama-assn.org
- Telemedicine Special Registrations for Controlled Substances — JAMA Health Forum jamanetwork.com
Frequently Asked Questions
Is it currently legal to get TRT through telehealth without an in-person visit?
Yes, under the current DEA/HHS temporary flexibility, which runs through December 31, 2026 — provided the prescriber is properly licensed, the diagnosis is lab-confirmed, and all other conditions in the rule are met.[4]
Why is testosterone treated differently from other medications in telehealth?
Because it's a Schedule III controlled substance under the Controlled Substances Act, which triggers the Ryan Haight Act's in-person evaluation requirement unless a specific exception or temporary flexibility applies.[1]
What happens after December 31, 2026?
Absent a permanent rule change before then, the in-person evaluation requirement is set to return for new controlled-substance telemedicine prescriptions, including TRT — a longer-term "special registration" framework has been proposed but wasn't finalized as of the most recent review.[7]
Does the DEA flexibility mean any provider can prescribe TRT to me?
No — the DEA rule only addresses the controlled-substance, in-person requirement. The provider still has to be licensed in your specific state and meet the standard of care for diagnosis and monitoring.[6]